Y. Segawa

K. Kiura, M. Tabata, H. Ueoka, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

K. Matsuo, K. Kiura, M. Tabata, 2006, British Journal of Cancer.

Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition.

N. Nogami, T. Shinkai, M. Nakata, 2005, Chest.

A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2009, Lung cancer.

Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications

S. Takashima, I. Oze, Y. Segawa, 2009, Journal of Cancer Research and Clinical Oncology.

[Long-term survivors of non-small cell lung cancer treated with non-surgical therapeutic modalities].

Y. Segawa, M. Kimura, M. Fujii, 1990, Gan no rinsho. Japan journal of cancer clinics.

Two cases of atypical carcinoid of the thymus.

K. Eguchi, M. Ida, M. Nakata, 2000, Internal medicine.

Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2003, Lung cancer.

Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.

M. Tsuboi, K. Mori, K. Eguchi, 2010, Anticancer research.

A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study

K. Kiura, M. Tabata, H. Ueoka, 2007, Cancer Chemotherapy and Pharmacology.

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.

M. Shibuya, Y. Ichinose, Y. Nishiwaki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

K. Kiura, M. Tabata, H. Ueoka, 2015, Lung cancer.

Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung.

K. Eguchi, T. Hanafusa, Y. Heike, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lung Cancer with Localized Ground-Glass Attenuation Represents Early-Stage Adenocarcinoma in Nonsmokers

Kenji Eguchi, Masao Nakata, Nobuhiko Seki, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features.

I. Takata, Y. Segawa, K. Mandai, 1997, Lung cancer.

Clinical investigation of bronchioloalveolar carcinoma: a retrospective analysis of 53 patients in a single institution.

M. Shimono, K. Hotta, M. Nakata, 1999, Anticancer research.

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

H. Mukai, H. Nakayama, Y. Segawa, 2016, International Cancer Conference Journal.

Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation.

I. Takata, Y. Segawa, M. Kataoka, 1996, Lung cancer.

[Phase II study of ifosfamide and vindesine combination of non-small cell lung cancer in elderly patients and patients with reduced renal function].

Y. Segawa, M. Fujii, S. Matsutomo, 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination.

N. Nogami, T. Shinkai, Y. Segawa, 2009, Lung cancer.

[A statistical analysis of serum sialyl Lewis X-1 (SLX), CEA, SCC and NSE levels in patients with lung cancer].

K. Kiura, M. Tabata, H. Ueoka, 1991, Nihon Kyobu Shikkan Gakkai zasshi.

Risk factors of chemotherapy‐induced nausea and vomiting: Index for personalized antiemetic prophylaxis

K. Kubota, Y. Segawa, T. Saeki, 2013, Cancer science.

Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer

K. Eguchi, K. Kiura, M. Tabata, 2000, Cancer Chemotherapy and Pharmacology.

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study

K. Kiura, M. Tabata, H. Ueoka, 1999, British Journal of Cancer.

Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.

K. Eguchi, K. Hotta, Y. Segawa, 1998, Anticancer research.

Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.

K. Kiura, M. Tabata, H. Ueoka, 2004, Anticancer research.

Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05/06.

Masato Nakamura, M. Takeuchi, Tatsuro Yamaguchi, 2016 .

A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.

M. Shibuya, N. Masuda, K. Kubota, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer

Y. Ichinose, H. Niitani, Y. Segawa, 2000, International Journal of Clinical Oncology.

A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy.

K. Eguchi, S. Umemura, N. Seki, 2002, Japanese journal of clinical oncology.

Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer: a 5- to 11-year follow-up.

K. Kiura, H. Ueoka, H. Kamei, 1993, Internal medicine.

Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2004, Lung cancer.

A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.

K. Kiura, M. Tabata, H. Ueoka, 2002, Lung cancer.

Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group

K. Eguchi, K. Kiura, M. Tabata, 2001, British Journal of Cancer.

[Double cancer in small cell lung cancer patients treated with intensive chemotherapy with or without radiation therapy].

H. Ueoka, Y. Segawa, K. Miyake, 1991, Nihon Kyobu Shikkan Gakkai zasshi.

[Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy].

K. Kiura, M. Tabata, H. Ueoka, 1992, Nihon Kyobu Shikkan Gakkai zasshi.

Pilot study of cyclophosphamide‐doxorubicin‐vincristine‐cisplatin‐etoposide hybrid chemotherapy in small cell lung cancer

K. Kiura, M. Tabata, H. Ueoka, 1993, Cancer.

Successful treatment of limited disease-small cell lung cancer with multimodality treatment consisting of concurrent chemoradiotherapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation and surgical resection.

K. Kiura, M. Tabata, H. Ueoka, 2003, Internal medicine.

Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients.

I. Takata, Y. Segawa, Y. Maeda, 1997, Lung cancer.

Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

Keitaro Matsuo, Masahiro Tabata, Susumu Kanazawa, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefits and Adverse Events Among Elderly Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: Analysis of the Okayama Lung Cancer Study Group Trial 0007

K. Matsuo, K. Kiura, M. Tabata, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of resected tumors that were not diagnosed histologically but were suspected of lung cancer preoperatively: PD1-3-5

I. Oze, N. Nogami, T. Shinkai, 2007 .

Parathyroid hormone‐related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia

K. Eguchi, K. Kiura, H. Ueoka, 2002, Cancer.

Neural cell adhesion molecule (NCAM) expression and clinical features in small cell lung cancer (SCLC), with reference to treatment outcome

K. Matsuo, M. Tabata, H. Ueoka, 1994 .

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

K. Eguchi, K. Kiura, M. Tabata, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

N. Sugimoto, K. Muro, A. Ohtsu, 2016, Gastric Cancer.

Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib

K. Kiura, Y. Segawa, N. Takigawa, 2008 .

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

S. Tomida, K. Nishio, Y. Iwamoto, 2020, JAMA oncology.

Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial

K. Kiura, M. Tabata, H. Ueoka, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.

K. Kiura, M. Tanimoto, K. Tsubouchi, 2012, Lung cancer.

Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary.

K. Yonemori, Y. Iwamoto, J. Tanizaki, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin‐Based Chemotherapy: A Subgroup Analysis of the JACCRO CC‐05/06 Trials

Masato Nakamura, M. Takeuchi, Tatsuro Yamaguchi, 2017, Clinical colorectal cancer.

Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.

K. Eguchi, K. Kiura, M. Tabata, 2007, Lung cancer.

Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer

K. Kiura, M. Tabata, H. Ueoka, 2006, Cancer.

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer

Masato Nakamura, H. Lenz, M. Takeuchi, 2016, Cancer biology & therapy.

STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.

S. Toyooka, K. Kiura, M. Tanimoto, 2012, Lung cancer.

Hypercalcemia-leukocytosis syndrome associated with lung cancer.

K. Eguchi, K. Kiura, H. Ueoka, 2004, Lung cancer.

Primary adenoid cystic carcinoma of the trachea effectively treated with the endoscopic Nd-YAG laser followed by radiation.

I. Takata, Y. Segawa, K. Mandai, 1996, Internal medicine.

Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.

I. Takata, Y. Segawa, N. Takigawa, 1996, Internal medicine.

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer

Masato Nakamura, H. Lenz, Wu Zhang, 2018, Molecular Cancer Therapeutics.

A fibrous histiocytoma with a polypoid pattern of growth in a major bronchus.

M. Nakata, H. Saeki, I. Takata, 1996, Internal medicine.

A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer

K. Kiura, M. Tabata, H. Ueoka, 2007, Cancer Chemotherapy and Pharmacology.

Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.

K. Kiura, M. Tabata, H. Ueoka, 2005, Anticancer research.

Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.

K. Kiura, M. Tabata, H. Ueoka, 1998, Anticancer Research.

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

S. Kudoh, K. Yoshimori, H. Niitani, 2001, British Journal of Cancer.

Phase I study of docetaxel and cisplatin for patients with previously untreated metastatic non-small-cell lung cancer: a Japanese cooperative study

K. Tominaga, H. Niitani, M. Yamakido, 2000, International Journal of Clinical Oncology.

Phase I study of topotecan and cisplatin in patients with small cell lung cancer.

Hiroshi Sakai, Yutaka Nishiwaki, Takashi Seto, 2011, Japanese journal of clinical oncology.

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

Masato Nakamura, M. Takeuchi, Tatsuro Yamaguchi, 2017, Targeted Oncology.

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Masato Nakamura, M. Takeuchi, Takao Takahashi, 2020, British Journal of Cancer.

[Serum neuron specific enolase (NSE) levels in patients with non small cell lung cancer].

H. Ueoka, Y. Segawa, T. Maeda, 1992, Nihon Kyobu Shikkan Gakkai zasshi.

A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV‐PVP for the treatment of patients with small cell lung carcinoma

K. Kiura, M. Tabata, H. Ueoka, 1998, Cancer.

Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience

K. Kiura, M. Tabata, H. Ueoka, 2008, Journal of Cancer Research and Clinical Oncology.

Two cases of small cell lung cancer presenting an unusual pattern of progression mimicking pleural mesothelioma

K. Eguchi, K. Hotta, I. Takata, 1998, International Journal of Clinical Oncology.

Secondary Primary Cancer Following Chemoradiation for Non-Small-Cell Lung Cancer

K. Kiura, Y. Segawa, N. Takigawa, 2008 .

Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma.

Kenji Eguchi, Masao Nakata, Nobuhiko Seki, 2010, Lung cancer.

Comparison in prognosis after VATS lobectomy and open lobectomy for stage I lung cancer

T. Shinkai, M. Nakata, Y. Segawa, 2007, Surgical Endoscopy.

Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).

Y. Nishimura, M. Fukuoka, N. Yamamoto, 2007, International journal of radiation oncology, biology, physics.

Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: radiation-induced lung toxicity.

K. Eguchi, S. Takashima, M. Ida, 2000, International journal of radiation oncology, biology, physics.

Immunohistochemical detection of P-glycoprotein and carcinoembryonic antigen in small cell lung cancer: with reference to predictability of response to chemotherapy.

K. Kiura, M. Tabata, H. Ueoka, 1993, Acta Medica Okayama.

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

K. Kiura, M. Tabata, M. Tanimoto, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2007 .

Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

K. Kiura, M. Tabata, H. Ueoka, 2004, Cancer Chemotherapy and Pharmacology.

A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503

K. Matsuo, K. Kiura, M. Tabata, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in pts with NSCLC previously treated with platinum-based chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) trial 0503.

K. Matsuo, K. Kiura, M. Tabata, 2009, Journal of Clinical Oncology.

Psychological impact of informed consent in hospitalized cancer patients

K. Eguchi, I. Hyodo, Y. Segawa, 1999, Supportive Care in Cancer.

A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group

K. Eguchi, K. Kiura, M. Tabata, 1999, British Journal of Cancer.

[A case of small cell bronchogenic carcinoma accompanied by polyneuropathy and SIADH].

K. Kiura, M. Tabata, H. Ueoka, 1993, Nihon Kyobu Shikkan Gakkai zasshi.

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)

Masato Nakamura, K. Tanabe, M. Takeuchi, 2017, Gastric Cancer.

Phase I study of cisplatin, docetaxel and irinotecan for advanced non-small cell lung cancer (NSCLC)

K. Eguchi, K. Kiura, H. Ueoka, 2000 .

Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer: OLCSG 0007

K. Matsuo, K. Kiura, M. Tabata, 2008 .

Primary lung cancer associated with diffuse granulomatous lesions in the pulmonary parenchyma.

I. Takata, Y. Segawa, H. Mogami, 1996, Internal medicine.

Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.

K. Kiura, M. Tabata, H. Ueoka, 1993, Acta medica Okayama.

Clinical investigation of atypical adenomatous hyperplasia of the lung.

K. Eguchi, M. Ida, M. Shimono, 1999, Lung cancer.

STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.

S. Toyooka, K. Kiura, M. Tanimoto, 2012, Lung cancer.

Phase I study of topotecan and cisplatin in patients with small cell lung cancer.

Y. Ichinose, Y. Nishiwaki, K. Kiura, 2011, Japanese journal of clinical oncology.

K. Matsuo, K. Kiura, M. Tabata, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.